“Darnitsa” made 12 new brands of medicines available05 August 2021
During 6 months of 2021, the pharmaceutical company Darnitsa launched 12 new brands of drugs for treating nervous and cardiovascular system diseases and pain management, the company's press service reports.
New drugs’ safety profile was confirmed in clinical trials. Some of the new products were created in cooperation with European pharmaceutical manufacturers.
Andrii Obrizan, the General Director of Darnitsa Pharmaceutical Company: “Darnitsa’s goal is to quickly bring new products to the market and thus expand the accessibility of treatment for the population. In the first half of 2021 we increased our investment in R&D by 10% and plan to release 25 new drugs by the end of the year. This number includes 10 products that will be released ahead of schedule due to digitalization of several processes and transition to electronic pharmaceutical document management.
Thus, in the first half of the year the company launched DVATSE LONG, DVATSE 200 in the category of over-the-counter drugs for the treatment of acute and chronic diseases of the bronchopulmonary system; ERIDEZ-DARNITSA to help eliminate symptoms associated with allergic rhinitis and urticaria and RITOSSE® IVY to be used in a complex therapy of wet cough.
New drugs from the company's prescription portfolio are aimed at treating dementia caused by Alzheimer's disease (MEMTEK®), schizophrenia and type I bipolar disorder (MINTEGRA), and one is for prevention and local treatment of infectious lesions (VEROMISTIN®).
In addition, in July, Darnitsa introduced a DARFEN® branded line of products that consists of four preparations in the form of gels, patches and oral forms - to combat pain and inflammation in adults and children beginning 3 months’ age.
Pharmaceutical company "Darnitsa" was founded in 1930. Since 1998, it has been the leader in Ukraine in terms of medicinal production in physical terms. The company's mission is to help healthcare professionals and patients improve their quality of life through science, innovation and accessibility. The company's portfolio includes 210 brands of medicines. The company has 14 GMP certified production lines. Darnitsa's products are exported to 15 countries. The beneficiaries of the company are the Zagoriy family.